Immvira’s scientific objectives are based on numerous experimental designs of oHSV and outcomes of clinical trials. Founded in 2015, Immvira is backed by investors that include Shanghai Healthcare Capital, Yonghua Capital, Cowin Capital, Huagai Capital, and MF Capital and is headquartered in Shenzhen.